Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: A nationwide case-crossover study

Stroke

Volumn 41, Issue 9, 2010, Pages 1884-1890

  Chang, Chia Hsuin ^a,b   Shau, Wen Yi ^c   Kuo, Chuei Wen ^d   Chen, Shu Ting ^e   Lai, Mei Shu ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Center for Drug Evaluation   (Taiwan)

^d National Health Insurance Mediation Committee   (Taiwan)

^e Office of Statistics   (Taiwan)

Author keywords

acute stroke; cerebral infarct; cerebrovascular disease; intracerebral hemorrhage; nonsteroidal anti inflammatory drugs

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MEFENAMIC ACID; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHINESE; DATA BASE; DISEASE CLASSIFICATION; DRUG SAFETY; FEMALE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STROKE; AGED; CEREBRAL HEMORRHAGE; CROSSOVER PROCEDURE; FACTUAL DATABASE; MIDDLE AGED; RISK; TAIWAN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CROSS-OVER STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK; STROKE; TAIWAN;

EID: 77956416571     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.585828     Document Type: Article

References (29)

1. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ. 2006;332:1302-1308.
2. McGettigan P, Henry D. Cardiovascular risk and inhibition of cycloox-ygenase: a systematic review of the observational studies of selective and non-selective inhibitors of cyclooxygenase 2. JAMA. 2006;296: 1633-1644.
3. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomized controlled trials. Ann Rheum Dis. 2007;66:1296-1304.
4. Henekens CH, Borzak S. Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2008;13:41-50.
5. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease anti-inflammatory prevention trial (ADAPT). PLoS Clin Trials. 2006;1:e33.
6. Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke. 2006;37:1725-1730.
7. Roumie CL, Mitchel EF, Kaltenbach L, Arbogast PG, Gideon P, Griffin MR. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke. 2008;39:2037-2045.
8. Haag MDM, Bos MJ, Hofman A, Koudstaal PJ, Breteler MMB, Stricker BHC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Stroke. 2008;168:1219-1224.
9. Bak S, Andersen M, Tsiropoulos I, Garcia Rodriguez LA, Hallas J, Christensen K, Gaist D, Qureshi AI. Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study. Stroke. 2003;34:379-386.
10. Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk of primary intrace-rebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study. BMJ. 1999;318:759-764.
11. Saloheimo P, Juvela S, Hillbom M. Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. Stroke. 2001;32:399-404.
12. Johnsen SP, Pedersen L, Friis S, Blot WJ, McLaughlin JK, Olsen JH, Sorensen HT. Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hospitalization for intracerebral hemorrhage: a population-based case-control study. Stroke. 2003;34:387-391.
13. Juvela S, Gaist D, Bak S, Johnsen SP, Pedersen L, Sorensen HT, Friis S, Olsen JH, Blot WJ, McLaughlin JK. Nonsteroidal anti-inflammatory drugs as risk factors for spontaneous intracerebral hemorrhage and aneu-rismal subarachnoid hemorrhage. Response. Stroke. 2003;34:e34-e36.
14. Choi NK, Park BJ, Jeong SW, Yu KH, Yoon BW. Nonaspirin nonste-roidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis Study. Stroke. 2008;39:845-849.
15. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21:193-221.
16. Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 1997;6(suppl 3):S51-S59.
17. Hallas J, Bjerrum L, Stovring H, Andersen M. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Am J Epidemiol. 2008; 168:966-973.
18. Wen CP, Tsai SP, Chung WSI. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med. 2008;148:258-267.
19. WHO Collaborating Centre for Drug Statistics Methodology. Defined daily dose: definition and general considerations. Available at www.whocc.no/ddd/ definition-and-general-considera/. Accessed March 29, 2010.
20. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Kober L, Madsen M, Torp-Pedersen C. Risk of death or reinfarction associated with the use of selective cyclo-oxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113: 2906-2913.
21. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, Sorensen R, Folke F, Buch P, Gadsboll N, Rasmussen S, Poulsen HE, Kober L, Madsen M, Torp-Pedersen C. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169: 141-149.
22. Strom BL, Berlin JA, Kinman JL, Spitz PW, Hennessy S, Feldman H, Kimmel S, Carson JL. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA. 1996;275:376-382.
23. Feldman HI, Kinman JL, Berlin JA, Hennessy S, Kimmel SE, Farrar J, Carson JL, Strom BL. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med. 1997;126:193-199.
24. Garcia Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158: 33-39.
25. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005; 165:490-496.
26. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296:1619-1632.
27. Solomon SD, Pfeffer MA, McMurray JJV, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; for the APC, PreSAP Trial investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028-1035.
28. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cylooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005;142:481-489.
29. Singh G, Graham D, Wang H, Mithal A, Triadafilopoulos G. Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis. 2006;65:S61.